Literature DB >> 17180691

Fasciola hepatica: ultrastructural effects of a combination of triclabendazole and clorsulon against mature fluke.

M Meaney1, J Allister, B McKinstry, K McLaughlin, G P Brennan, A B Forbes, I Fairweather.   

Abstract

A study has been carried out to investigate the ultrastructural effects of triclabendazole (TCBZ) at half-normal concentration, clorsulon at half-normal concentration, and a combination of these two drugs against mature Fasciola hepatica. The Cullompton TCBZ-susceptible isolate was used for these experiments. Flukes were incubated for 24 h in vitro in TCBZ sulphoxide (7.5 microg/ml), clorsulon (5 microg/ml), or a combination of the two drugs. For the in vivo experiment, rats were dosed with TCBZ (5 mg/kg body weight), clorsulon (5 mg/kg body weight), or a combination of the two drugs, and flukes recovered after 48 h. Fine structural changes within the tegumental syncytium and tegumental cells were assessed by transmission electron microscopy. Treatment with the combination of drugs produced greater disruption to the flukes than the individual drugs at half-normal concentrations, both in vivo and in vitro; also than TCBZ.SO at normal concentration in vitro. The changes observed aid in the understanding of the gross changes to the tegumental surface described previously (Meaney M, Allister J, McKinstry B, McLaughlin K, Brennan GP, Forbes AB, Fairweather I. Parasitol Res 99:609-621, 2006). The results indicate that there are additive effects between TCBZ and clorsulon and suggest that the use of drug combinations would be of value in the treatment of TCBZ-resistant fluke.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17180691     DOI: 10.1007/s00436-006-0378-6

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  27 in total

Review 1.  Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.

Authors:  Jürg Utzinger; Jennifer Keiser; Xiao Shuhua; Marcel Tanner; Burton H Singer
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  A light and electron microscopic study on the synergistic effect of pyrantel and the febantel metabolite febendazole on adult Toxocara canis in vitro.

Authors:  Heinz Mehlhorn; Elena Hanser; Achim Harder; O Hansen; Norbert Mencke; Roland Schaper
Journal:  Parasitol Res       Date:  2003-04-01       Impact factor: 2.289

Review 3.  Triclabendazole: new skills to unravel an old(ish) enigma.

Authors:  I Fairweather
Journal:  J Helminthol       Date:  2005-09       Impact factor: 2.170

4.  Fasciola hepatica: morphological effects of a combination of triclabendazole and clorsulon against mature fluke.

Authors:  M Meaney; J Allister; B McKinstry; K McLaughlin; G P Brennan; A B Forbes; I Fairweather
Journal:  Parasitol Res       Date:  2006-08-02       Impact factor: 2.289

Review 5.  Fasciolicides: efficacy, actions, resistance and its management.

Authors:  I Fairweather; J C Boray
Journal:  Vet J       Date:  1999-09       Impact factor: 2.688

6.  Could ivermectin have a synergic effect with albendazole in hydatidosis therapy?

Authors:  N Casado; M J Moreno; M A Urrea-París; F Rodríguez-Caabeiro
Journal:  Parasitol Res       Date:  2002-02       Impact factor: 2.289

7.  Could ivermectin have a synergic effect with albendazole in hydatidosis therapy?

Authors:  M J Moreno; N Casado; M A Urrea-París; F Rodríguez-Caabeiro
Journal:  Parasitol Res       Date:  2002-03-20       Impact factor: 2.289

Review 8.  Methods to sustain drug efficacy in helminth control programmes.

Authors:  M Albonico
Journal:  Acta Trop       Date:  2003-05       Impact factor: 3.112

9.  The kinetics of triclabendazole disposition in sheep.

Authors:  D R Hennessy; E Lacey; J W Steel; R K Prichard
Journal:  J Vet Pharmacol Ther       Date:  1987-03       Impact factor: 1.786

Review 10.  Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control.

Authors:  Jürg Utzinger; Jennifer Keiser
Journal:  Expert Opin Pharmacother       Date:  2004-02       Impact factor: 3.889

View more
  11 in total

1.  Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica.

Authors:  Catherine Devine; Gerard P Brennan; Carlos E Lanusse; Luis I Alvarez; Alan Trudgett; Elizabeth Hoey; Ian Fairweather
Journal:  Parasitol Res       Date:  2010-03-25       Impact factor: 2.289

2.  Ultrastructural changes induced in the tegument and gut of Fasciola hepatica following in vivo and in vitro drug treatment with nitroxynil (Trodax).

Authors:  B McKinstry; G P Brennan; L Halferty; A B Forbes; I Fairweather
Journal:  Parasitol Res       Date:  2007-06-08       Impact factor: 2.289

3.  Surface changes in adult Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha.

Authors:  M McConville; G P Brennan; A Flanagan; R E B Hanna; H W J Edgar; R Castillo; A Hernández-Campos; I Fairweather
Journal:  Parasitol Res       Date:  2009-05-21       Impact factor: 2.289

4.  Fasciola hepatica: disruption of spermatogenesis by the fasciolicide compound alpha.

Authors:  Maeve McConville; Robert E B Hanna; Gerard P Brennan; Maurice McCoy; Hillary W J Edgar; Shirley McConnell; Rafael Castillo; Alicia Hernández-Campos; Ian Fairweather
Journal:  Parasitol Res       Date:  2009-11-18       Impact factor: 2.289

5.  Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.

Authors:  C Devine; G P Brennan; C E Lanusse; L I Alvarez; A Trudgett; E Hoey; I Fairweather
Journal:  Parasitol Res       Date:  2011-03-26       Impact factor: 2.289

6.  Erratum to: inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.

Authors:  C Devine; G P Brennan; C E Lanusse; L I Alvarez; A Trudgett; E Hoey; I Fairweather
Journal:  Parasitol Res       Date:  2011-08-14       Impact factor: 2.289

7.  Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole.

Authors:  Catherine Devine; Gerard P Brennan; Carlos E Lanusse; Luis I Alvarez; Alan Trudgett; Elizabeth Hoey; Ian Fairweather
Journal:  Parasitol Res       Date:  2010-05-30       Impact factor: 2.289

8.  Efficient copper-based DNA cleavers from carboxylate benzimidazole ligands.

Authors:  Víctor A Barrera-Guzmán; Edgar O Rodríguez-Hernández; Naytzé Ortíz-Pastrana; Ricardo Domínguez-González; Ana B Caballero; Patrick Gamez; Norah Barba-Behrens
Journal:  J Biol Inorg Chem       Date:  2018-08-03       Impact factor: 3.358

9.  An integrated transcriptomics and proteomics analysis of the secretome of the helminth pathogen Fasciola hepatica: proteins associated with invasion and infection of the mammalian host.

Authors:  Mark W Robinson; Ranjeeta Menon; Sheila M Donnelly; John P Dalton; Shoba Ranganathan
Journal:  Mol Cell Proteomics       Date:  2009-05-14       Impact factor: 5.911

10.  Morphological response of triclabendazole-susceptible and triclabendazole-resistant isolates of Fasciola hepatica to treatment in vitro with nitroxynil (Trodax).

Authors:  B McKinstry; L Halferty; G P Brennan; I Fairweather
Journal:  Parasitol Res       Date:  2008-11-18       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.